Skip to main content

Dr. Richard M. Stone, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Medical school
Harvard Medical School (1981)
Years since graduation
45
In the NPI registry since
2006
Medicare patients seen, 2024
178

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1981Medical school: Harvard Medical School
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MA license 53417

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
178
Services billed
490
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes325132
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes13135
Established patient office or other outpatient visit, 40-54 minutes4332
New patient office or other outpatient visit, 60-74 minutes1919
Hospital discharge day management, 30 minutes or less1616

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Acyclovir
Other prescribers in Boston, MA
16
Hydroxyurea
Other prescribers in Boston, MA
15
Imatinib Mesylate12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 13 payments worth $10,947 in total to this clinician.

By company
Epizyme, Inc.$3,988
Syndax Pharmaceuticals, Inc.$3,803
E.r. Squibb & Sons, L.l.c.$2,865
Celgene Corporation$292
By type
Consulting Fee$9,653
Travel and Lodging$1,041
Food and Beverage$254

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 1, 2025E.r. Squibb & Sons, L.l.c.
Jul 1, 2025
Consulting Fee$2,865
Jul 10, 2025Syndax Pharmaceuticals, Inc.
Jul 10, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$2,800
Jun 18, 2025Epizyme, Inc.
Jun 18, 2025
Consulting Fee
Tazverik · Oncology
$2,538
Jul 2, 2025Epizyme, Inc.
Jul 2, 2025
Consulting Fee
Tazverik · Oncology
$1,450
Jul 10, 2025Syndax Pharmaceuticals, Inc.
Jul 10, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind
$377
Jul 10, 2025Syndax Pharmaceuticals, Inc.
Jul 10, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind
$258
Dec 5, 2025Celgene Corporation
Dec 5, 2025
Travel and Lodging
travel to Orlando, FL
$197
Jul 10, 2025Syndax Pharmaceuticals, Inc.
Jul 10, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO
$147
Jul 10, 2025Syndax Pharmaceuticals, Inc.
Jul 10, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to DENVER, CO · in-kind
$61.14

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $230,509 in research payments for these studies, mostly to the institutions running them.

  • A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
    Janssen Research & Development, LLC
  • A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
    Novartis Pharmaceuticals Corporation
  • A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
    Syndax Pharmaceuticals, Inc.
  • A phase i, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced hematologic malignancies…
    Servier Pharmaceuticals LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 8, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1528036894. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.